The Food and Drug Administration (FDA) has issued its “Strategic Plan for Regulatory Science,” a document deemed to be the agency’s “blueprint for overhauling the science it uses to develop and evaluate food, medicines, and medical devices.” Among the agency’s priorities are modernizing toxicology, stimulating innovation in clinical evaluations and personalized medicine, supporting new approaches to improve product manufacturing, facilitating the development of medical countermeasures to protect against threats to U.S. and global health and security, and strengthening social and behavioral sciences to help consumers and professionals with their decisions about regulated products. FDA intends to involve stakeholders from the private sector in accomplishing its plan.